Ran Liu1, Shenglong Cao1, Ya Hua1, Richard F Keep1, Yining Huang1, Guohua Xi2. 1. From the Department of Neurosurgery, University of Michigan, Ann Arbor (R.L., S.C., Y.H., R.F.K., G.X.); and Department of Neurology, Peking University First Hospital, Beijing, China (R.L., Y.H.). 2. From the Department of Neurosurgery, University of Michigan, Ann Arbor (R.L., S.C., Y.H., R.F.K., G.X.); and Department of Neurology, Peking University First Hospital, Beijing, China (R.L., Y.H.). guohuaxi@umich.edu.
Abstract
BACKGROUND AND PURPOSE: CD163, a receptor for hemoglobin, is involved in hemoglobin clearance after intracerebral hemorrhage (ICH). In contrast to microglial/macrophage CD163, neuronal CD163 hemoglobin has not been well studied. This study examined the expression of neuronal CD163 in a pig model of ICH and in vitro rat cortical neurons and the impact of deferoxamine on that expression. METHODS: There were 2 parts to this study. In the in vivo part, piglets had injection of autologous blood into the right frontal lobe. The time course of CD163 expression and the effect of deferoxamine on the expression of CD163 after ICH were determined in the grey matter. In the in vitro part, the levels of CD163 and neuronal death and the effect of deferoxamine were examined in rat cortical neurons culture treated with hemoglobin. RESULTS: CD163-positive cells were found, and the CD163 protein levels were upregulated in the ipsilateral grey matter after ICH. The CD163 levels peaked at days 1 and 3. The CD163-positive cells were colocated with NeuN-positive, heme oxygenase-2-positive, and terminal deoxynucleatidyl transferase dUTP nick end labeling-positive cells. Deferoxamine treatment attenuated ICH-induced CD163 upregulation and significantly reduced both brain CD163 and hemoglobin levels at day 3. Treating neuronal cultures with hemoglobin for 24 hours resulted in CD163 upregulation and increased cell death. Deferoxamine significantly attenuated the hemoglobin-induced neuronal death and CD163 upregulation. CONCLUSIONS: CD163 is expressed in neurons and upregulated after ICH. Deferoxamine reduced ICH-induced CD163 upregulation and brain cell death in vivo and hemoglobin-induced CD163 upregulation and neuronal death in vitro.
BACKGROUND AND PURPOSE:CD163, a receptor for hemoglobin, is involved in hemoglobin clearance after intracerebral hemorrhage (ICH). In contrast to microglial/macrophage CD163, neuronal CD163 hemoglobin has not been well studied. This study examined the expression of neuronal CD163 in a pig model of ICH and in vitro rat cortical neurons and the impact of deferoxamine on that expression. METHODS: There were 2 parts to this study. In the in vivo part, piglets had injection of autologous blood into the right frontal lobe. The time course of CD163 expression and the effect of deferoxamine on the expression of CD163 after ICH were determined in the grey matter. In the in vitro part, the levels of CD163 and neuronal death and the effect of deferoxamine were examined in rat cortical neurons culture treated with hemoglobin. RESULTS:CD163-positive cells were found, and the CD163 protein levels were upregulated in the ipsilateral grey matter after ICH. The CD163 levels peaked at days 1 and 3. The CD163-positive cells were colocated with NeuN-positive, heme oxygenase-2-positive, and terminal deoxynucleatidyl transferase dUTP nick end labeling-positive cells. Deferoxamine treatment attenuated ICH-induced CD163 upregulation and significantly reduced both brain CD163 and hemoglobin levels at day 3. Treating neuronal cultures with hemoglobin for 24 hours resulted in CD163 upregulation and increased cell death. Deferoxamine significantly attenuated the hemoglobin-induced neuronal death and CD163 upregulation. CONCLUSIONS:CD163 is expressed in neurons and upregulated after ICH. Deferoxamine reduced ICH-induced CD163 upregulation and brain cell death in vivo and hemoglobin-induced CD163 upregulation and neuronal death in vitro.
Authors: Laura Ruth Guelman; Romina María del Luján Pagotto; Cecilia Gabriela Di Toro; Luis María Zieher Journal: Neurotoxicol Teratol Date: 2004 May-Jun Impact factor: 3.763
Authors: Saravanan S Karuppagounder; Ishraq Alim; Soah J Khim; Megan W Bourassa; Sama F Sleiman; Roseleen John; Cyrille C Thinnes; Tzu-Lan Yeh; Marina Demetriades; Sandra Neitemeier; Dana Cruz; Irina Gazaryan; David W Killilea; Lewis Morgenstern; Guohua Xi; Richard F Keep; Timothy Schallert; Ryan V Tappero; Jian Zhong; Sunghee Cho; Frederick R Maxfield; Theodore R Holman; Carsten Culmsee; Guo-Hua Fong; Yijing Su; Guo-li Ming; Hongjun Song; John W Cave; Christopher J Schofield; Frederick Colbourne; Giovanni Coppola; Rajiv R Ratan Journal: Sci Transl Med Date: 2016-03-02 Impact factor: 17.956
Authors: Hye-Yeong Kim; Ran Li; Thomas S C Ng; Gabriel Courties; Christopher Blake Rodell; Mark Prytyskach; Rainer H Kohler; Mikael J Pittet; Matthias Nahrendorf; Ralph Weissleder; Miles A Miller Journal: ACS Nano Date: 2018-12-11 Impact factor: 15.881
Authors: D Andrew Wilkinson; Aditya S Pandey; B Gregory Thompson; Richard F Keep; Ya Hua; Guohua Xi Journal: Neuropharmacology Date: 2017-09-22 Impact factor: 5.250
Authors: Ben Gaastra; Dianxu Ren; Sheila Alexander; Ellen R Bennett; Dawn M Bielawski; Spiros L Blackburn; Mark K Borsody; Sylvain Doré; James Galea; Patrick Garland; Tian He; Koji Iihara; Yoichiro Kawamura; Jenna L Leclerc; James F Meschia; Michael A Pizzi; Rafael J Tamargo; Wuyang Yang; Paul A Nyquist; Diederik O Bulters; Ian Galea Journal: Neurology Date: 2019-04-05 Impact factor: 9.910
Authors: Grant C O'Connell; Madison B Treadway; Connie S Tennant; Noelle Lucke-Wold; Paul D Chantler; Taura L Barr Journal: Transl Stroke Res Date: 2018-03-17 Impact factor: 6.829
Authors: Lei Ye; Yong-Sheng Fang; Xiao-Xue Li; Yi Gao; Sheng-Sheng Liu; Qiang Chen; Qiang Wu; Hong-Wei Cheng; Wei-Dong Du Journal: Ann Transl Med Date: 2021-04
Authors: Anan Shtaya; Leslie R Bridges; Rebecca Williams; Sarah Trippier; Liqun Zhang; Anthony C Pereira; James A R Nicoll; Delphine Boche; Atticus H Hainsworth Journal: Stroke Date: 2021-07-20 Impact factor: 7.914